CD274 and bladder transitional cell carcinoma: In the IMvigor210-BLCA cohort, patients with low TMEindex exhibited significant therapeutic advantages to anti-PD-L1 therapy and a markedly prolonged OS (P < 0.001; Fig. 8A).